Reach out and get your patients to read

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.

Built environments, but not social and economic environments, were negatively associated with BMI and overweight or obesity status, with a stronger association among adolescents with longer exposure to their built environment.

A study found that children with acute concussions could have less symptom burden with an earlier return to school.